Clinical Trial Update: A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the tolerability of REGN17372 in combination with Linvoseltamab for adults with relapsed and refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma

Drugs mentioned

• Linvoseltamab
• REGN17372

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1, Phase 2 | Status: RECRUITING